We are releasing a comprehensive update on both the operational and financial evolution of Aurora Spine Corporation ($ASG).
As always, we’ve included our usual short overview, but if you’re already familiar with the company, feel free to skip straight to the insights from our 1-on-1 interview.

Priority Briefings. Investing is dynamic, so our research never sits still. We don’t file a report and walk away; we maintain an active, ongoing dialogue with the key stakeholders and management teams of our past, present, and future holdings.
Think of these briefs as your “insider access” to those calls. We bring you contextualized highlights and actionable updates. You’ll see exactly how the business is evolving in real-time, long before it hits the quarterly report.
This series is exclusively for 🧙♂️ Inner Circle members
None of the following should be construed as investment advice. Please consult a financial advisor before making any investment decision. You will find a full disclaimer at the end of this post.

Aurora Spine Corporation ($ASG) Brief
Aurora Spine is a medical technology disruptor turning the massive $20bn spinal implant market on its head.
Although it’s technically a Canadian-listed entity (trading on the TSXV), it is based in Carlsbad, California, and is one of the few hardware designers of minimally invasive surgery devices.
Unlike the old-school one-size-fits-all metal hardware that treats every spine the same, Aurora has developed smart implants that mimic a patient’s actual anatomy.
They are precision engineers of the human back, looking to fill the void for interventionalists and surgeons combined.
Product Overview
Aurora focuses on high-tech platforms designed to make surgeries faster, safer, and far less painful:
DEXA Platforms & Apollo Plates: Traditional spinal implants are often too stiff, causing them to sink into the bone over time. Aurora’s DEXA implants are 3D-printed to match a patient’s specific bone density. With a 4th US patent issued for the DEXA platform, commercial momentum is led by the DEXA-C (cervical) line alongside the re-released Apollo Cervical Plates, supported by the expanded DEXA-L system for the lumbar spine.
SiLO, SiLO-TFX & CornerLoc Alliance: Targeting Sacroiliac (SI) joint pain, these systems replace invasive procedures with small incisions to stabilize the joint. Supported by a settled patent dispute and a fresh royalty license on the SiLO-TFX, Aurora formed a nationwide commercial alliance with CornerLoc. The reciprocal partnership effectively doubles field sales reach by cross-selling joint fusion portfolios, pairing CornerLoc’s specialized SI fusion technologies and reimbursement network with Aurora’s implant engineering to serve both interventional pain physicians and orthopedic spine surgeons.
Zip & Aurora Biologics: Launched in late 2025, Aurora’s biologics line continues to scale alongside its flagship minimally invasive ZIP interspinous fusion implants. The company pairs these regenerative biologics with its implant systems to improve fusion rates and accelerate bone healing.
What We’re Looking To Understand Better?
Patent Cleanup
Management just overhauled their internal sales team while stamping out a nasty patent dispute over their flagship SILO TFX implant. The arbitration is settled and the new royalty deal is signed, but surgeons don’t return overnight.
Did the courtroom leave lasting scar tissue, or is the interventional pain business ready to snap back?
Margins Up or Down?
Cervical implants are flying (up 66%) and re-releasing the Apollo plate finally gives surgeons a complete setup. But moving product through third-party distributors rather than direct reps takes a bite out of the margin.
If lower-margin distributor volume drives revenue growth, does the bottom line ever reap the reward?
CornerLoc Victory or Failure?
Teaming up looks like an instant win on paper: cross-selling joint fusion gear to double surgical reach overnight. Yet field reps are notoriously territorial about pushing someone else’s hardware.
Why did the merger fail? And… Is this alliance an immediate revenue booster, or will everyday sales friction eat up the upside?
Liquidity Timebomb
Cash is down to roughly $360k. A $200k extension from an insider loan keeps the lights on, but it’s a tight cushion when running quarterly losses. Can aggressive receivables collection carry them across breakeven? Is heavy dilution just around the corner?
All of this and much more below…
If you want the full picture of the company, check out our write-up:
In Conversation with Matt Goldstone (Chief Commercial) and Trent Northcutt (Chief Executive) of Aurora Spine
Key Takeaways and Insights
Note: Even though the pessimism in this write-up is obvious, we will concede that at the start of the month we got filled on an order at C$0.10.
That’s caused by a combination of the powerful factors aligning, including:




